Zou Peixuan, Pan Yusong, Luo Wenjie, Huang Run, Lin Xiuling, Xie Yinghai
The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, China; School of Materials Science and Engineering, Anhui University of Science and Technology, Huainan, Anhui 232001, China.
The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, China; School of Materials Science and Engineering, Anhui University of Science and Technology, Huainan, Anhui 232001, China.
Colloids Surf B Biointerfaces. 2025 Oct;254:114784. doi: 10.1016/j.colsurfb.2025.114784. Epub 2025 May 16.
Chemo-photothermal synergistic therapy is an effective method for tumor treatment. Herein, the CuS/HKUST-1@PDA drug carrier was successfully prepared by a simple combination of in-situ partial vulcanization and in-situ polymerization technologies. The micro-structure, morphology, and functional groups of the prepared samples were characterized by XRD, SEM, TEM, BET, and FTIR technologies. The drug loading experiment verified that the CuS/HKUST-1@PDA possesses an excellent doxorubicin (DOX) drug loading capacity, whose drug loading capacity is as high as 88.7 %. The drug release indicated that CuS/HKUST-1@PDA drug carrier inherited pH-responsive drug release behavior, which it can release DOX in acidic conditions resembling the tumor microenvironment, while effectively containing the drug within the PDA coating under neutral conditions. The CuS/HKUST-1@PDA drug carrier demonstrated outstanding biocompatibility, sustaining cell viability above 80 % across a concentration range of 1.5-15 μg/mL. Moreover, the drug carrier realized chemo-Photothermal synergistic therapy triggered by near-infrared light in tumor treatment, reducing tumor cell viability to 28 % during in vitro cellular experiments. The innovative design and effective tumor treatment ability of the CuS/HKUST-1@PDA drug carrier highlight its significant potential in anticancer therapy.
化疗-光热协同疗法是一种有效的肿瘤治疗方法。在此,通过原位部分硫化和原位聚合技术的简单结合成功制备了CuS/HKUST-1@PDA药物载体。采用XRD、SEM、TEM、BET和FTIR技术对制备样品的微观结构、形态和官能团进行了表征。载药实验证实CuS/HKUST-1@PDA具有优异的阿霉素(DOX)载药能力,其载药量高达88.7%。药物释放表明CuS/HKUST-1@PDA药物载体继承了pH响应性药物释放行为,即在类似于肿瘤微环境的酸性条件下可释放DOX,而在中性条件下能有效地将药物包裹在PDA涂层内。CuS/HKUST-1@PDA药物载体表现出出色的生物相容性,在1.5-15μg/mL的浓度范围内细胞活力维持在80%以上。此外,该药物载体在肿瘤治疗中实现了近红外光触发的化疗-光热协同疗法,在体外细胞实验中将肿瘤细胞活力降低至28%。CuS/HKUST-1@PDA药物载体的创新设计和有效的肿瘤治疗能力突出了其在抗癌治疗中的巨大潜力。